AstraZeneca confirms new Imfinzi approval, shares steady on London listing

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 07:36.

AstraZeneca (US6549022043) underlines a new milestone for its oncology franchise after the latest US approval for Imfinzi in bladder cancer, while its primary listing on the London Stock Exchange keeps the group in the FTSE 100 benchmark as investors digest the news. According to Reuters, US regulators recently cleared Imfinzi as the first immunotherapy combination regimen for BCG-naive high-risk bladder cancer in the country, adding another indication to the drug’s label.

What Reuters reports on Imfinzi

The Reuters news feed shows that AstraZeneca’s Imfinzi has been approved in the United States as the first immunotherapy combination regimen for BCG-naive high-risk bladder cancer patients, marking a fresh regulatory success in a competitive oncology market. This indication expands Imfinzi beyond earlier approvals in lung cancer and other tumors, reinforcing AstraZeneca’s focus on immuno-oncology as a core growth pillar alongside targeted therapies and vaccines.

MarketScreener’s overview of AstraZeneca confirms that the group remains one of the largest constituents of the FTSE 100 index, with London-listed AstraZeneca shares trading around 13,290 pence in recent sessions and a market capitalization of roughly 206 billion pounds. That size gives the stock a prominent role in European healthcare indices and global pharma portfolios where peers include GlaxoSmithKline and Sanofi.

Analyst stance and key figures

Jefferies recently reiterated a Buy rating on AstraZeneca, according to a research summary captured by MarketScreener, underlining confidence in the pipeline and earnings trajectory despite increasing pricing pressure in Europe. The London quote data from Hargreaves Lansdown shows AstraZeneca trading at a price to earnings ratio of about 26.5 based on its latest results, with a dividend yield close to 1.8 percent and a dividend per share of 1.595 pounds following the March 2026 payment date.

Hargreaves Lansdown’s share detail also indicates that AstraZeneca’s London listing opened at 13,240 pence in the latest session and closed near 13,234 pence, suggesting muted day-to-day volatility for the shares. The same data points to daily trading volumes exceeding 1.8 million shares, underlining the stock’s liquidity for institutional and retail investors alike compared with many smaller healthcare names in the FTSE 100.

The product behind the stock

Imfinzi, AstraZeneca’s immunotherapy drug also known by its generic name durvalumab, is a monoclonal antibody targeting the PD-L1 protein to help the immune system recognize and attack cancer cells, with approved uses across lung and now high-risk bladder cancer per the recent US clearance. It sits alongside Tagrisso and Enhertu in AstraZeneca’s oncology portfolio, which has become a central driver of revenue growth and R&D investment for the group.

Where the stock trades today

The AstraZeneca shares (US6549022043) trade primarily on the London Stock Exchange, where they were last quoted around 13,290 pence as of 2026-06-22, 16:30 local time, according to Hargreaves Lansdown and MarketScreener, with the US ADR following the London price in dollar terms.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any security, or a solicitation of any kind. All data are based on sources believed to be reliable at the time of publication but may change without notice.